Beacon Investment Advisory Services Inc. Acquires 1,751 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Beacon Investment Advisory Services Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,259 shares of the biopharmaceutical company's stock after buying an additional 1,751 shares during the quarter. Beacon Investment Advisory Services Inc.'s holdings in Regeneron Pharmaceuticals were worth $16,654,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. TD Private Client Wealth LLC increased its position in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after buying an additional 15 shares in the last quarter. Adirondack Trust Co. raised its holdings in shares of Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 18 shares during the last quarter. Prestige Wealth Management Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 23.2% in the fourth quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock valued at $72,000 after purchasing an additional 19 shares in the last quarter. Kingswood Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after buying an additional 19 shares in the last quarter. Finally, Creative Financial Designs Inc. ADV grew its stake in shares of Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after acquiring an additional 19 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $7.75 during trading hours on Thursday, reaching $564.64. The company had a trading volume of 1,037,647 shares, compared to its average volume of 903,298. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The firm has a market cap of $60.96 billion, a PE ratio of 14.37, a price-to-earnings-growth ratio of 2.14 and a beta of 0.33. The business has a fifty day simple moving average of $543.59 and a 200 day simple moving average of $611.77.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 EPS. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.62%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $837.61.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.